Avaxia CEO Barbara Fox is Named an EY Entrepreneur Of The Year™ 2014 Award Finalist in New England

First Page		Document Content
Date: 2014-05-22 11:31:36 Pharmacology Monoclonal antibodies Immune system Immunology Ulcerative colitis TNF inhibitor Mucositis Inflammatory bowel disease Biologic Medicine Health Autoimmune diseases		Avaxia CEO Barbara Fox is Named an EY Entrepreneur Of The Year™ 2014 Award Finalist in New England Add to Reading List Source URL: www.avaxiabiologics.com Download Document from Source Website File Size: 259,34 KB Share Document on Facebook

	CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium DocID: 1vhgc - View Document
	ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for DocID: 1v3WA - View Document
	Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent DocID: 1uTpm - View Document
	INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy DocID: 1uPEI - View Document
	Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra, DocID: 1ujGa - View Document